Published in N Engl J Med on September 13, 1984
Antacid maintenance therapy in the prevention of duodenal ulcer relapse. Gut (1988) 1.54
Cigarette smoking, gastric acid secretion, and serum pepsinogen I concentrations in duodenal ulcer patients. Gut (1985) 1.20
Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime. Gut (1990) 1.01
Increased gastric secretory capacity in smokers without gastrointestinal lesions. Gut (1986) 0.99
Outpatient endoscopic survey of smoking and peptic ulcer. Gut (1986) 0.95
The role of polyamines in gastric mucus synthesis inhibited by cigarette smoke or its extract. Gut (2000) 0.90
Sex and smoking differences in duodenal ulcer mortality. Am J Public Health (1986) 0.90
Smoking and malignant disease: a general practice study. J R Coll Gen Pract (1984) 0.88
Misoprostol in the treatment of duodenal ulcer. A multicenter double-blind placebo-controlled study. Dig Dis Sci (1985) 0.87
Perforated duodenal ulcer and cigarette smoking. J R Soc Med (1988) 0.84
Peptic ulcer disease: absence of antibodies stimulating the histamine sensitive adenylate cyclase of gastric mucosal cells. Gut (1991) 0.84
Low dose maintenance treatment with cimetidine in duodenal ulcer: intermediate-term results. Postgrad Med J (1986) 0.83
Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. Int J Environ Res Public Health (2010) 0.82
Efficacy of misoprostol (twice daily dosage) in acute healing of duodenal ulcer. A multicenter double-blind controlled trial. Dig Dis Sci (1986) 0.82
Smoking and mortality from peptic ulcer in the United Kingdom. Gut (1986) 0.81
Therapeutic aspects of prostaglandins in the treatment of peptic ulcer disease. Dig Dis Sci (1986) 0.80
Recent advances in the treatment of duodenal ulcer disease. A surgical perspective. West J Med (1987) 0.79
Cigarette smoking and duodenal ulcer. Gut (1985) 0.79
Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol (2016) 0.78
Clinical markers of slow healing and relapsing gastric ulcer. Gut (1987) 0.77
Predictors of duodenal ulcer healing during treatment with cimetidine. Gut (1990) 0.77
Prognosis of chronic duodenal ulcer: a prospective study of the effects of demographic and environmental factors and ulcer healing. Gut (1987) 0.76
Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit. BMJ (1988) 0.75
Abuse of elderly subject of Toronto conference. CMAJ (1988) 0.75
Peptic ulcer disease. Pathophysiology and current medical management. West J Med (1987) 0.75
Depression of salivary epidermal growth factor by smoking. BMJ (1992) 0.75
Acid, motility, and ulcers: a comparison of cisapride with placebo in the prevention of duodenal ulcer relapse. Gut (1993) 0.75
Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements. Gut (1994) 0.75
Penile ulceration in Crohn's disease. Gut (1986) 0.75
Resistant duodenal ulcer: when, why and what to do? Postgrad Med J (1988) 0.75
Production of clinical notes in personal injury litigation in Ontario. CMAJ (1988) 0.75
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 9.77
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA (2001) 8.40
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform (1999) 7.68
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01
Norwalk virus genome cloning and characterization. Science (1990) 5.83
Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet (1987) 5.02
Proteolytic enhancement of rotavirus infectivity: molecular mechanisms. J Virol (1981) 4.87
Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet (2005) 4.65
Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem (1978) 4.61
In vitro transcription and translation of simian rotavirus SA11 gene products. J Virol (1980) 4.40
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol (1999) 4.13
Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology (1998) 4.12
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A (1999) 3.91
Detection of Norwalk virus in stool by polymerase chain reaction. J Clin Microbiol (1992) 3.82
A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology (1989) 3.66
A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A (2000) 3.66
Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol (1996) 3.57
The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33
Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure. J Bacteriol (1996) 3.32
Variants of the 3' region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J Clin Microbiol (1998) 3.31
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology (1994) 3.22
Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol (1996) 3.20
N-acetylneuraminyllactose-binding fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen. Infect Immun (1988) 3.16
Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem (1979) 3.15
Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet (1991) 3.09
Smoking, health, and survival: prospects in Bangladesh. Lancet (1981) 3.05
Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure. J Clin Invest (1980) 2.99
Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol (1993) 2.96
Ultrastructural localization of rotavirus antigens using colloidal gold. Virus Res (1984) 2.95
Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology (1992) 2.83
Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J (1999) 2.80
Factors controlling amino acid incorporation by ribosomes from krebs II mouse ascites-tumour cells. Biochem J (1966) 2.77
The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet (2001) 2.71
Identification, synthesis, and modifications of simian rotavirus SA11 polypeptides in infected cells. J Virol (1982) 2.67
The decision to breastfeed in the United States: does race matter? Pediatrics (2001) 2.67
A plaque assay for the simian rotavirus SAII. J Gen Virol (1979) 2.65
Intracellular Ca(2+) dynamics and the stability of ventricular tachycardia. Biophys J (1999) 2.65
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1997) 2.63
Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology (1982) 2.60
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A (2000) 2.58
Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet (1995) 2.57
Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology (1999) 2.54
Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology (2002) 2.49
Rotavirus stability and inactivation. J Gen Virol (1979) 2.48
Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother (1997) 2.47
Helicobacter pylori infection: genetic and environmental influences. A study of twins. Ann Intern Med (1994) 2.47
Relationship between the cagA 3' repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology (1999) 2.44
Patients, payers, and paradigm shifts: what to do about Helicobacter pylori. Am J Gastroenterol (1996) 2.43
Amphibian declines: an immunological perspective. Dev Comp Immunol (1999) 2.41
Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter (1998) 2.39
Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis (1998) 2.38
Comparison of custom and prefabricated orthoses in the initial treatment of proximal plantar fasciitis. Foot Ankle Int (1999) 2.37
Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol (1997) 2.37
Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc (1994) 2.36
A reevaluation of the roles of the O2-dependent and O2-independent microbicidal systems of phagocytes. Rev Infect Dis (1983) 2.35
The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism. Clin Exp Immunol (1966) 2.34
Race, family income, and low birth weight. Am J Epidemiol (1991) 2.30
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet (1995) 2.29
Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem (1989) 2.29
Assessment of sternal vascularity with single photon emission computed tomography after harvesting of the internal thoracic artery. J Thorac Cardiovasc Surg (1999) 2.24
Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet (1996) 2.22
Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20
High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun (1992) 2.17
Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol (1994) 2.16
Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. J Clin Invest (1975) 2.16
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther (2013) 2.15
Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut (1994) 2.14
Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut (1990) 2.13
Prevalence and determinants of nutritional blindness in Bangladeshi children. World Health Stat Q (1985) 2.12
Pancreatic-biliary ascariasis: experience of 300 cases. Am J Gastroenterol (1997) 2.10
Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol (1996) 2.09
Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology (1987) 2.07
Nucleic acid hybridization studies of mycobactin-dependent mycobacteria. J Clin Microbiol (1988) 2.06
Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol (1987) 2.05
Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest (1985) 2.05
Killing of gram-negative bacteria by polymorphonuclear leukocytes: role of an O2-independent bactericidal system. J Clin Invest (1982) 2.04
Non-isotopic and sensitive method for diagnosis of maternally-inherited diabetes and deafness. Diabetologia (1994) 2.03
Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol (1993) 2.00
An evolving view of Saturn's dynamic rings. Science (2010) 1.99
Latex sensitization in health care workers and in the US general population. Am J Epidemiol (2001) 1.98
Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem (2001) 1.98
Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect (2000) 1.97
Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun (1995) 1.97
Behaviorally conditioned immunosuppression. Psychosom Med (1975) 1.97
Helicobacter pylori in the drinking water in Peru. Gastroenterology (1996) 1.95
Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction. J Clin Microbiol (1993) 1.94
Role of charge and hydrophobic interactions in the action of the bactericidal/permeability-increasing protein of neutrophils on gram-negative bacteria. J Clin Invest (1983) 1.93
Detection of Mycobacterium avium subspecies paratuberculosis in Crohn's diseased tissues by in situ hybridization. Am J Gastroenterol (2001) 1.93
Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology (2012) 1.92
Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch (1998) 1.91
Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol (1996) 1.89
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med (1999) 1.88